Alphatec Holdings (ATEC) Panoramica del titolo
Alphatec Holdings, Inc. è una società di tecnologia medica che progetta, sviluppa e fa progredire tecnologie per il trattamento chirurgico dei disturbi della colonna vertebrale negli Stati Uniti e a livello internazionale. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 5/6 |
| Crescita futura | 5/6 |
| Prestazioni passate | 0/6 |
| Salute finanziaria | 2/6 |
| Dividendi | 0/6 |
Premi
Analisi del rischio
ATEC Community Fair Values
Create NarrativeSee what 15 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Alphatec Holdings, Inc.
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$7.91 |
| Massimo di 52 settimane | US$23.29 |
| Minimo di 52 settimane | US$6.82 |
| Beta | 0.87 |
| Variazione di 1 mese | 5.19% |
| Variazione a 3 mesi | -36.77% |
| Variazione di 1 anno | -33.64% |
| Variazione a 3 anni | -48.44% |
| Variazione a 5 anni | -46.08% |
| Variazione dall'IPO | -92.66% |
Notizie e aggiornamenti recenti
Aggiornamento della narrazione • Jun 05
ATEC: New Bank Facility And 2026 Outlook Will Support Upside
Analysts have trimmed their price target for Alphatec Holdings from $20.00 to $11.00, citing updated assumptions for revenue growth, profit margins, and a lower future P/E multiple as key drivers of the change. What's in the News Alphatec reported Q1 2026 total revenue of $192 million, with surgical revenue growth of 17% and total revenue growth of 14%, according to recent earnings coverage (source: Alphatec Reports Strong Q1 2026 Growth and Secures New Bank Facility).Seeking Alpha • May 19
Alphatec - Slower Growth Seems Priced In Here
Summary Alphatec Holdings shares have dropped two-thirds YTD, now trading at just over 2x sales, reflecting sharply decelerating growth and persistent losses. Q1 2026 revenue grew only 14% to $192.1M, prompting a slight full-year sales guidance cut; adjusted EBITDA margins improved but remain heavily adjusted. Despite a $466M net debt load and ongoing dilution, Alphatec demonstrates real operating leverage, with manageable losses and a credible path toward profitability. Slowing topline growth and elusive margins temper enthusiasm, but current valuation appears compelling versus medtech peers, making Alphatec a speculative yet interesting play. Read the full article on Seeking Alpha
Aggiornamento della narrazione • May 14
ATEC: 2026 Surgical Revenue Focus Will Support Future Upside Potential
Analysts have reduced their price target for Alphatec Holdings from about $24.62 to about $17.33 as they adjust assumptions for discount rate, revenue growth, profit margin, and future P/E in their models. What's in the News Alphatec Holdings issued earnings guidance for the fiscal year ending December 31, 2026, targeting total revenue of about $882 million, with surgical revenue expected to grow 17% as part of that outlook (corporate guidance).Recent updates
Aggiornamento della narrazione • Jun 05
ATEC: New Bank Facility And 2026 Outlook Will Support Upside
Analysts have trimmed their price target for Alphatec Holdings from $20.00 to $11.00, citing updated assumptions for revenue growth, profit margins, and a lower future P/E multiple as key drivers of the change. What's in the News Alphatec reported Q1 2026 total revenue of $192 million, with surgical revenue growth of 17% and total revenue growth of 14%, according to recent earnings coverage (source: Alphatec Reports Strong Q1 2026 Growth and Secures New Bank Facility).Seeking Alpha • May 19
Alphatec - Slower Growth Seems Priced In Here
Summary Alphatec Holdings shares have dropped two-thirds YTD, now trading at just over 2x sales, reflecting sharply decelerating growth and persistent losses. Q1 2026 revenue grew only 14% to $192.1M, prompting a slight full-year sales guidance cut; adjusted EBITDA margins improved but remain heavily adjusted. Despite a $466M net debt load and ongoing dilution, Alphatec demonstrates real operating leverage, with manageable losses and a credible path toward profitability. Slowing topline growth and elusive margins temper enthusiasm, but current valuation appears compelling versus medtech peers, making Alphatec a speculative yet interesting play. Read the full article on Seeking AlphaAggiornamento della narrazione • May 14
ATEC: 2026 Surgical Revenue Focus Will Support Future Upside Potential
Analysts have reduced their price target for Alphatec Holdings from about $24.62 to about $17.33 as they adjust assumptions for discount rate, revenue growth, profit margin, and future P/E in their models. What's in the News Alphatec Holdings issued earnings guidance for the fiscal year ending December 31, 2026, targeting total revenue of about $882 million, with surgical revenue expected to grow 17% as part of that outlook (corporate guidance).
Aggiornamento della narrazione • Apr 29
ATEC: 2026 Revenue Guidance Will Drive Constructive Upside Case
Analysts have kept their $28.00 price target for Alphatec Holdings unchanged, noting that only modest adjustments to assumptions around discount rate, revenue growth, profit margin and future P/E offset one another in their valuation work. What's in the News Alphatec Holdings reaffirmed earnings guidance for the fiscal year ending December 31, 2026, indicating no change to its previously communicated outlook.Aggiornamento della narrazione • Apr 15
ATEC: 2026 Revenue Outlook Will Support Bullish Return Potential
Analysts have kept their $28.00 price target on Alphatec Holdings unchanged, citing updated assumptions that include a higher discount rate, stronger modeled revenue and profit margins, and a lower future P/E multiple that together balance out in their valuation work. What's in the News Alphatec Holdings reaffirmed earnings guidance for the fiscal year ending December 31, 2026, maintaining its outlook for that period.Aggiornamento della narrazione • Mar 31
ATEC: 2026 Revenue Outlook And Biologics Partnership Will Support Upside
Analysts have trimmed their price target for Alphatec Holdings from $22.00 to $20.00, citing updated assumptions for revenue growth, profit margins and future P/E that together point to a more measured long term outlook for the shares. What's in the News Reaffirmed earnings guidance for the fiscal year ending December 31, 2026, with total revenue expected to approximate $890 million, described as about $126 million or 17% above full year 2025 revenue (Corporate Guidance).Aggiornamento della narrazione • Mar 17
ATEC: 2026 Revenue Outlook And Spine Biologics Partnership Will Support Upside
Analysts have left their $28.00 price target for Alphatec Holdings unchanged, citing a slightly higher assumed discount rate, a moderated revenue growth outlook, stronger projected profit margins, and a lower future P/E as key factors supporting the steady valuation. What's in the News Alphatec Holdings reaffirmed earnings guidance for the fiscal year ending December 31, 2026, with total revenue expected to approximate $890 million.Aggiornamento della narrazione • Mar 03
ATEC: 2026 Revenue Outlook And Biologics Partnership Will Support Upside Potential
Analysts have adjusted their Alphatec Holdings target to $24.62, reflecting updated assumptions that combine slightly lower expected revenue growth with higher projected profit margins and a reduced future P/E multiple, while applying a somewhat higher discount rate. What's in the News Alphatec Holdings reaffirmed earnings guidance for the fiscal year ending December 31, 2026, with total revenue expected to approximate $890 million, described as about $126 million or 17% higher than full year 2025 revenue (company guidance).Aggiornamento della narrazione • Feb 17
ATEC: 2026 Revenue Guidance And Spine Biologics Deal Will Drive Upside
Analysts have maintained their $28.00 price target for Alphatec Holdings, citing steady model adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions as reasons to hold their prior valuation line. What's in the News Alphatec Holdings issued revenue guidance for fiscal 2026, indicating expected total revenue of approximately $890m for the year ended December 31, 2026 (Corporate Guidance).Aggiornamento della narrazione • Feb 03
ATEC: Partnership And 2026 Revenue Outlook Will Reshape Spine Biologics Opportunity
Analysts have raised their fair value estimate for Alphatec Holdings from $23.00 to $28.00, citing updated assumptions for discount rates, revenue growth, profit margins, and future P/E that they believe better reflect the company’s current outlook. What's in the News Alphatec Holdings issued revenue guidance for fiscal 2026, indicating expected total revenue of about $890 million compared to full year 2025 (Corporate Guidance).Aggiornamento della narrazione • Jan 20
ATEC: Higher 2026 Revenue Outlook And New Partnership Will Support Upside
Analysts have lifted their price target on Alphatec Holdings from US$14.00 to US$22.00, citing updated assumptions around discount rate, revenue growth, profit margins and future P/E as the key drivers of the change. What's in the News Alphatec Holdings issued revenue guidance for fiscal 2026, indicating expected total revenue of approximately US$890 million for the year.Articolo di analisi • Jan 06
Are Alphatec Holdings, Inc. (NASDAQ:ATEC) Investors Paying Above The Intrinsic Value?
Key Insights Alphatec Holdings' estimated fair value is US$17.32 based on 2 Stage Free Cash Flow to Equity Alphatec...Aggiornamento della narrazione • Jan 06
ATEC: Higher 2025 Revenue Guidance Will Support A More Optimistic Outlook
Analysts have inched their price target for Alphatec Holdings higher to about $24.62 from $24.00, reflecting small tweaks to fair value estimates, discount rate assumptions, and a slightly higher future P/E multiple in their models. What's in the News Alphatec Holdings raised earnings guidance for the fiscal year ending December 31, 2025, indicating updated expectations for the business outlook.Aggiornamento della narrazione • Dec 14
ATEC: Revenue Will Reach 760 Million As Outlook Remains Favorable
Analysts have modestly raised their price target on Alphatec Holdings by 0.25 dollars to 24.00 dollars, reflecting slightly higher long term valuation multiples despite only marginal tweaks to growth, margin and discount rate assumptions. What's in the News Alphatec Holdings raised its earnings guidance for fiscal 2025, now expecting total revenue to increase 24 percent to 760 million dollars, compared with the prior outlook of 742 million dollars (company guidance filing) Valuation Changes Fair Value Estimate has risen slightly to 24.00 dollars from 23.75 dollars, reflecting a modest uplift in long term valuation.Aggiornamento della narrazione • Nov 29
ATEC: Revenue Will Reach $760 Million As Guidance Increases And Outlook Remains Steady
Analysts have maintained their fair value price target for Alphatec Holdings at $23.75, citing only minor adjustments to underlying financial assumptions along with a steady outlook for growth and profitability. What's in the News Alphatec Holdings raised its earnings guidance for the fiscal year ending December 31, 2025, reflecting increased confidence in the company's outlook (Key Developments).Aggiornamento della narrazione • Nov 15
ATEC: Total Revenue Will Reach $760 Million Next Year
Narrative Update on Alphatec Holdings: Analyst Price Target Revision Analysts have increased their price target for Alphatec Holdings from $20.54 to $23.75. This change reflects revised financial assumptions and updated expectations for the company’s future performance.Aggiornamento della narrazione • Nov 01
ATEC: Improved Margins And Revenue Projections Will Shape Future Performance
Analysts have raised their price target for Alphatec Holdings from $19.41 to $20.54 per share, citing improved profit margin forecasts and stronger projected revenue growth as key reasons for the increased valuation. What's in the News Alphatec Holdings, Inc.Articolo di analisi • Oct 05
Not Many Are Piling Into Alphatec Holdings, Inc. (NASDAQ:ATEC) Just Yet
With a median price-to-sales (or "P/S") ratio of close to 2.8x in the Medical Equipment industry in the United States...Aggiornamento della narrazione • Sep 20
Expanding Spine Care And Integrated Tech Will Drive Future Opportunities
The slight increase in Alphatec Holdings’ future P/E ratio reflects higher growth expectations, which has contributed to a modest rise in its consensus analyst price target from $18.95 to $19.41. What's in the News Raised full-year 2025 revenue guidance to $742 million, up 21% year-over-year, surpassing previous forecast of $734 million.Articolo di analisi • Jul 28
Are Investors Undervaluing Alphatec Holdings, Inc. (NASDAQ:ATEC) By 43%?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Alphatec Holdings fair value estimate is US$19.10 Current...Articolo di analisi • Jul 09
Should You Investigate Alphatec Holdings, Inc. (NASDAQ:ATEC) At US$11.60?
While Alphatec Holdings, Inc. ( NASDAQ:ATEC ) might not have the largest market cap around , it led the NASDAQGS...Nuova narrazione • May 27
Robotics And Minimally Invasive Techniques Will Expand Spine Care
Innovative spine solutions and expanding minimally invasive offerings position Alphatec for sustained revenue growth and margin expansion amid rising global spine care demand.Articolo di analisi • May 11
Alphatec Holdings, Inc. (NASDAQ:ATEC) Stock Rockets 25% But Many Are Still Ignoring The Company
Alphatec Holdings, Inc. ( NASDAQ:ATEC ) shares have had a really impressive month, gaining 25% after a shaky period...Articolo di analisi • Apr 20
Alphatec Holdings (NASDAQ:ATEC) Is Making Moderate Use Of Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Articolo di analisi • Mar 01
Alphatec Holdings, Inc. (NASDAQ:ATEC) Just Released Its Full-Year Results And Analysts Are Updating Their Estimates
Shareholders of Alphatec Holdings, Inc. ( NASDAQ:ATEC ) will be pleased this week, given that the stock price is up 18...Articolo di analisi • Jan 18
Alphatec Holdings, Inc. (NASDAQ:ATEC) Stock Rockets 31% But Many Are Still Ignoring The Company
Despite an already strong run, Alphatec Holdings, Inc. ( NASDAQ:ATEC ) shares have been powering on, with a gain of 31...Articolo di analisi • Dec 19
Here's Why Alphatec Holdings (NASDAQ:ATEC) Can Afford Some Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Dec 03
Alphatec: A Big Recovery
Summary Alphatec, a medtech company focused on spine solutions, has faced investor concerns due to continued losses, cash burn, and increasing debt despite revenue growth. Shares plunged 40% after Q2 earnings, but have recovered following the release of the third quarter results following management's comments about positive cash flow in Q4. Management's optimistic outlook is further backed up by significant improvement in EBITDA seen in 2025. Despite the positive reaction, Alphatec still needs to prove its ability to reduce debt and avoid further dilution while executing its growth plans. Read the full article on Seeking AlphaArticolo di analisi • Nov 01
Alphatec Holdings, Inc. (NASDAQ:ATEC) Soars 50% But It's A Story Of Risk Vs Reward
Alphatec Holdings, Inc. ( NASDAQ:ATEC ) shareholders would be excited to see that the share price has had a great...Articolo di analisi • Aug 29
Positive Sentiment Still Eludes Alphatec Holdings, Inc. (NASDAQ:ATEC) Following 38% Share Price Slump
The Alphatec Holdings, Inc. ( NASDAQ:ATEC ) share price has fared very poorly over the last month, falling by a...Articolo di analisi • Aug 28
We Think Alphatec Holdings (NASDAQ:ATEC) Has A Fair Chunk Of Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Rendimenti per gli azionisti
| ATEC | US Medical Equipment | US Mercato | |
|---|---|---|---|
| 7D | 5.7% | 2.5% | -2.7% |
| 1Y | -33.6% | -20.4% | 22.5% |
Ritorno vs Industria: ATEC ha avuto una performance inferiore rispetto al US Medical Equipment che ha registrato un rendimento -20.4 % nell'ultimo anno.
Rendimento vs Mercato: ATEC ha avuto una performance inferiore al mercato US che ha registrato un rendimento 22.5 % nell'ultimo anno.
Volatilità dei prezzi
| ATEC volatility | |
|---|---|
| ATEC Average Weekly Movement | 12.6% |
| Medical Equipment Industry Average Movement | 8.7% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.1% |
Prezzo delle azioni stabile: Negli ultimi 3 mesi il prezzo delle azioni di ATEC è stato volatile rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale ( 13% ) di ATEC è rimasta stabile nell'ultimo anno, ma è comunque superiore al 75% delle azioni US.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 1990 | 913 | Pat Miles | www.atecspine.com |
Alphatec Holdings, Inc. è una società di tecnologia medica che progetta, sviluppa e fa progredire le tecnologie per il trattamento chirurgico dei disturbi spinali negli Stati Uniti e a livello internazionale. L'azienda produce e vende impianti, strumenti, apparecchiature di imaging e parti di ricambio. Offre la piattaforma di prodotti Alpha InformatiX, che comprende il sistema di imaging EOS, che fornisce immagini di tutto il corpo; il sistema SafeOp Neural InformatiX, che automatizza il monitoraggio elettromiografico, del potenziale evocato somatosensoriale e del potenziale evocato motorio; Valence, un sistema intraoperatorio che integra la navigazione e la robotica nelle procedure spinali, nonché i sistemi Sigma Prone TransPsoas (PTP) Access e PTP Patient Positioning.
Alphatec Holdings, Inc. Riepilogo dei fondamenti
| ATEC statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$1.23b |
| Utili (TTM) | -US$125.36m |
| Ricavi(TTM) | US$787.08m |
1.5x
Rapporto P/S-9.7x
Rapporto P/EATEC è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| ATEC Conto economico (TTM) | |
|---|---|
| Ricavi | US$787.08m |
| Costo del fatturato | US$234.72m |
| Profitto lordo | US$552.37m |
| Altre spese | US$677.73m |
| Utili | -US$125.36m |
Ultimi utili riportati
Mar 31, 2026
Prossima data di guadagno
n/a
| Utile per azione (EPS) | -0.82 |
| Margine lordo | 70.18% |
| Margine di profitto netto | -15.93% |
| Rapporto debito/patrimonio netto | 3,140.9% |
Come si è comportato ATEC nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/06/08 17:50 |
| Prezzo dell'azione a fine giornata | 2026/06/08 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Alphatec Holdings, Inc. è coperta da 25 analisti. 11 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Matthew Miksic | Barclays |
| Caitlin Cronin | Canaccord Genuity |
| Tao Levy | Deutsche Bank |